MB-101 (MustBio)

N/A

Report date: 2026/03/19 16:53:27

Base Information

Drug NameMB-101 (MustBio)

Drug Alias Nameanti-CD3/anti-PD-L1 bispecific T-cell engager (MustBio)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionProgrammed death-ligand 1 modulatorsImmunostimulantsT cell surface glycoprotein CD3 modulators +[4]

TargetsT cell surface glycoprotein CD3Programmed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMUSTBIO Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesMUSTBIO Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A